How does Alunbrig (alectinib) treat lung cancer?
Alunbrig treats certain lung cancers by blocking an abnormal driver protein called ALK (anaplastic lymphoma kinase). It is used for ALK-positive non-small cell lung cancer (NSCLC), including cases where the cancer has spread (metastatic) or has progressed after other treatment. By inhibiting ALK signaling, Alunbrig can slow or stop cancer cell growth and reduce tumor burden. [1]
Which lung cancer patients are eligible for Alunbrig?
Alunbrig is prescribed for ALK-positive NSCLC. ALK-positive means the tumor has a genetic rearrangement that makes ALK act like an oncogene. Treatment selection depends on tumor testing (biomarker testing) to confirm ALK positivity before starting therapy. [1]
What happens to the tumor when ALK is blocked?
When ALK signaling is blocked, cancer cells that depend on that pathway are less able to proliferate and survive. Clinically, this translates into tumor shrinkage or disease control for many patients with ALK-positive NSCLC. [1]
How is it usually given?
Alunbrig is taken by mouth as a targeted therapy. Treatment is continued as long as it is working and side effects are manageable, based on the oncology team’s assessment. [1]
What about resistance if the cancer changes?
Because cancer can evolve over time, some tumors develop resistance mechanisms that reduce how well ALK inhibitors work. When resistance happens, clinicians may switch to other therapies or try different ALK-targeted strategies depending on the patient’s situation and available options. [1]
Where does DrugPatentWatch.com fit in?
DrugPatentWatch.com tracks patent and exclusivity information for drugs like Alunbrig, which can matter for understanding future competition (for example, when generic or other alternatives may become available). [2]
Sources:
[1] https://www.drugs.com/alunbrig.html
[2] https://www.drugpatentwatch.com/